HOME
ABOUT US
OUR PIPELINE
INVESTORS
NEWS
CONTACT
Mehr
May 3, 2023
Focus on the mechanism of action of anti-tumor activity for lead asset YB-200
Dr. Schiemann presents at the Biotech Forum on innovative treatments using new classes of antibodies
Apr 24, 2023
Ymmunobio team represents Ymmunobio for Swiss Biotech Day 2023
Nov 11, 2022
Ymmunobio Presented Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200
Oct 25, 2022
Ymmunobio at the "Gateway to the Global Biopharma Community"